{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:59:21Z","timestamp":1790085561530,"version":"4.0.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300750"],"award-info":[{"award-number":["82300750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202203021221260"],"award-info":[{"award-number":["202203021221260"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119883","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:09:08Z","timestamp":1788466148000},"page":"119883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fibroblast activation protein-\u03b1 in liver fibrosis and hepatocarcinogenesis: Stromal remodeling, molecular imaging, and theranostic targeting"],"prefix":"10.1016","volume":"203","author":[{"given":"Peng","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7783","key":"10.1016\/j.biopha.2026.119883_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib2","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/hep.31987","article-title":"Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice","volume":"74","author":"Yang","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep.20853","article-title":"Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line","volume":"42","author":"Wang","year":"2005","journal-title":"Hepatology"},{"issue":"51","key":"10.1016\/j.biopha.2026.119883_bib4","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.31848","article-title":"Perivenous stellate cells are the main source of myofibroblasts and cancer-associated fibroblasts formed after chronic liver injuries","volume":"74","author":"Wang","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.biopha.2026.119883_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105094","article-title":"Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS. One"},{"issue":"9","key":"10.1016\/j.biopha.2026.119883_bib7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.20122344","article-title":"Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia","volume":"210","author":"Roberts","year":"2013","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","article-title":"Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules","volume":"48","author":"Shi","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.biopha.2026.119883_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1034\/j.1600-0676.2002.01503.x","article-title":"Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection","volume":"22","author":"Levy","year":"2002","journal-title":"Liver"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib12","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1038\/s41467-020-19668-y","article-title":"AdipoR1\/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis","volume":"11","author":"Xu","year":"2020","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.biopha.2026.119883_bib13","doi-asserted-by":"crossref","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.febslet.2006.01.087","article-title":"Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2-Pro1-cleaving specificity","volume":"580","author":"Edosada","year":"2006","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.biopha.2026.119883_bib15","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein with a (4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold","volume":"5","author":"Jansen","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.biopha.2026.119883_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of 99mTc-labeled FAPI tracers for SPECT imaging and 188Re therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"16","key":"10.1016\/j.biopha.2026.119883_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.biopha.2026.119883_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djs336","article-title":"Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug","volume":"104","author":"Brennen","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/anie.201506262","article-title":"Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation","volume":"55","author":"Ji","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"10","key":"10.1016\/j.biopha.2026.119883_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hep4.1298","article-title":"Inhibitors of arginine-glycine-aspartic acid-binding integrins reduce development of liver fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"3","author":"Ulmasov","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2026.119883_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119883_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.640566","article-title":"vitro and in situ activity-based labeling of fibroblast activation protein with UAMC1110-derived probes","volume":"9","author":"Van Rymenant","year":"2021","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.123.266345","article-title":"Preclinical development of PNT6555, a boronic acid-based fibroblast activation protein-\u03b1-targeted radiotheranostic for imaging and treatment of FAP-positive tumors","volume":"65","author":"Poplawski","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib27","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","article-title":"Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis","volume":"15","author":"Yang","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41420-024-01995-4","article-title":"IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway","volume":"10","author":"Sun","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.biopha.2026.119883_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2023.02.032","article-title":"Hypoxia-inducible factor 1\u03b1\/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis","volume":"653","author":"Kou","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119883_bib31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.celrep.2019.10.024","article-title":"Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis","volume":"29","author":"Dobie","year":"2019","journal-title":"Cell. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119883_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41422-023-00831-1","article-title":"An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression","volume":"33","author":"Wu","year":"2023","journal-title":"Cell. Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib33","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein-targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/MCB.20.3.1089-1094.2000","article-title":"Targeted disruption of mouse fibroblast activation protein","volume":"20","author":"Niedermeyer","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108252","article-title":"Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target","volume":"33","author":"Wei","year":"2020","journal-title":"Cell. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J. Exp. Med."},{"issue":"14","key":"10.1016\/j.biopha.2026.119883_bib37","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell."},{"issue":"50","key":"10.1016\/j.biopha.2026.119883_bib39","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7693","key":"10.1016\/j.biopha.2026.119883_bib40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib41","first-page":"727","article-title":"Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119883_bib42","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib43","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI88845","article-title":"Mesothelin\/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib44","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/hep.22265","article-title":"The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells","volume":"47","author":"Mart\u00edn-V\u00edlchez","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.gastro.2005.03.089","article-title":"Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells","volume":"129","author":"Schulze-Krebs","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib46","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2020.01.027","article-title":"Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib47","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib48","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2013.02.016","article-title":"Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy","volume":"59","author":"Hern\u00e1ndez-Gea","year":"2013","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jhep.2015.04.011","article-title":"The Hippo pathway effector YAP controls mouse hepatic stellate cell activation","volume":"63","author":"Mannaerts","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119883_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117801","article-title":"Targeting the FAP\u03b1\/Integrin \u03b1v\u03b21 complex attenuates hepatic stellate cell activation and liver fibrosis","volume":"247","author":"Guan","year":"2026","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib52","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2020.08.033","article-title":"Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling","volume":"74","author":"Winkler","year":"2021","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119883_bib53","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1136\/gutjnl-2013-306294","article-title":"CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis","volume":"63","author":"Ehling","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib54","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s42003-021-02611-2","article-title":"Targeting integrin \u03b1v\u03b23 by a rationally designed protein for chronic liver disease treatment","volume":"4","author":"Turaga","year":"2021","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib55","doi-asserted-by":"crossref","first-page":"G471","DOI":"10.1152\/ajpgi.00153.2017","article-title":"Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury","volume":"314","author":"Konishi","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib56","doi-asserted-by":"crossref","first-page":"G234","DOI":"10.1152\/ajpgi.00254.2021","article-title":"Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis","volume":"322","author":"Kostallari","year":"2022","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.22351","article-title":"Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence","volume":"48","author":"DeLeve","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib58","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jso.21613","article-title":"Mechanical stiffness of liver tissues in relation to integrin \u03b21 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma","volume":"102","author":"Zhao","year":"2010","journal-title":"J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/cancers12020490","article-title":"Stiffer matrix accelerates migration of hepatocellular carcinoma cells through enhanced aerobic glycolysis via the MAPK-YAP signaling","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/hep.26429","article-title":"Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice","volume":"58","author":"Pradere","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib61","first-page":"272","article-title":"A TLR2\/S100A9\/CXCL-2 signaling network in hepatic stellate cells promotes liver fibrosis","volume":"146","author":"Moles","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119883_bib62","article-title":"Activated hepatic stellate cells induce infiltration and formation of CD163+ macrophages via CCL2\/CCR2 pathway","volume":"8","author":"Xi","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.22952","article-title":"CCR2 promotes hepatic fibrosis in mice","volume":"50","author":"Seki","year":"2009","journal-title":"Hepatology"},{"issue":"46","key":"10.1016\/j.biopha.2026.119883_bib64","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.biopha.2026.119883_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184694","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","author":"Puengel","year":"2017","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib66","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib68","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"issue":"82","key":"10.1016\/j.biopha.2026.119883_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add8945","article-title":"Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation","volume":"8","author":"Fabre","year":"2023","journal-title":"Sci. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib70","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-\u03b2 signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib71","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and Toll-like receptor 4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell."},{"issue":"7725","key":"10.1016\/j.biopha.2026.119883_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","author":"Seehawer","year":"2018","journal-title":"Nature"},{"issue":"7931","key":"10.1016\/j.biopha.2026.119883_bib73","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.biopha.2026.119883_bib74","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib76","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","article-title":"Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","article-title":"Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell. Discov."},{"issue":"22","key":"10.1016\/j.biopha.2026.119883_bib79","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/0008-5472.CAN-20-4226","article-title":"FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness","volume":"81","author":"Loh","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib80","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41467-017-02583-0","article-title":"Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer","volume":"9","author":"Fang","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of hepatocellular carcinoma: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib82","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib83","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib84","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"issue":"7886","key":"10.1016\/j.biopha.2026.119883_bib85","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","article-title":"Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion","volume":"599","author":"Sun","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12414","article-title":"Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib","volume":"43","author":"Eun","year":"2023","journal-title":"Cancer Commun. (Lond. )"},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib87","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.celrep.2016.04.019","article-title":"Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met\/FRA1\/HEY1 signaling","volume":"15","author":"Lau","year":"2016","journal-title":"Cell. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119883_bib89","article-title":"FAP-activatable theranostic agent inhibiting VEGF expression for liver fibrosis therapy","author":"Zeng","year":"2026","journal-title":"Adv. Healthc. Mater."},{"issue":"7","key":"10.1016\/j.biopha.2026.119883_bib90","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib91","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib92","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/cbin.12154","article-title":"Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity","volume":"48","author":"Wang","year":"2024","journal-title":"Cell. Biol. Int."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib93","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib94","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1038\/s41467-024-52308-3","article-title":"A FAP\u03b1-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib95","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2013.06.026","article-title":"Molecular MRI of collagen to diagnose and stage liver fibrosis","volume":"59","author":"Fuchs","year":"2013","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119883_bib96","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1007\/s00259-024-06773-z","article-title":"Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation","volume":"51","author":"Song","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib97","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41598-025-34877-5","article-title":"A pilot human-based study of 68Ga-FAPI-04 PET\/CT in staging liver fibrosis and preliminary comparison to FIB-4 and FibroScan","volume":"16","author":"Li","year":"2026","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib98","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2012.04.035","article-title":"Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models","volume":"57","author":"Polasek","year":"2012","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119883_bib99","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119883_bib100","article-title":"68Ga-FAPI-04 versus 18F-FDG PET\/CT in the detection of hepatocellular carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib101","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-025-01289-5","article-title":"A fibroblast activation protein targeted optical tracer for identifying primary and metastatic sarcoma during resection","volume":"15","author":"Azari","year":"2025","journal-title":"EJNMMI Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119883_bib102","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"13","key":"10.1016\/j.biopha.2026.119883_bib103","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.biopha.2026.119883_bib104","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","article-title":"Comparison of baseline 68Ga-FAPI and 18F-FDG PET\/CT for prediction of response and outcome in unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib","volume":"64","author":"Wu","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib105","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.acra.2024.11.034","article-title":"The value of machine learning-based radiomics model characterized by PET imaging with 68Ga-FAPI in assessing microvascular invasion of hepatocellular carcinoma","volume":"32","author":"Fan","year":"2025","journal-title":"Acad. Radiol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib106","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib107","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/s41467-022-35291-5","article-title":"Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib108","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","article-title":"18F]FAPI PET\/CT in evaluation of focal liver lesions with [18F]FDG non-avidity","volume":"50","author":"Zhang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib110","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib111","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119883_bib112","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1042\/BCJ20200749","article-title":"Integrin \u03b1v\u03b21 regulates procollagen I production through a non-canonical transforming growth factor \u03b2 signaling pathway in human hepatic stellate cells","volume":"478","author":"Reed","year":"2021","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib113","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-022-29186-8","article-title":"Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib114","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1258\/ebm.2011.011127","article-title":"Melittin attenuates liver injury in thioacetamide-treated mice through modulating inflammation and fibrogenesis","volume":"236","author":"Park","year":"2011","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib115","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/hep.28252","article-title":"Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes","volume":"63","author":"Ibrahim","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119883_bib116","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2022.12.020","article-title":"Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis","volume":"353","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.biopha.2026.119883_bib117","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acsnano.3c03217","article-title":"Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119883_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119616","article-title":"Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy","volume":"230","author":"Fan","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119883_bib119","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2018.05.032","article-title":"Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis","volume":"283","author":"Qiao","year":"2018","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib121","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3892\/mmr.2014.3048","article-title":"Celecoxib derivative OSU-03012 inhibits the proliferation and activation of hepatic stellate cells by inducing cell senescence","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib122","doi-asserted-by":"crossref","first-page":"9289","DOI":"10.1038\/s41598-017-09673-5","article-title":"Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-\u03b21\/Smads and PI3K\/Akt pathways","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119883_bib123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.04.022","article-title":"An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis","volume":"303","author":"Li","year":"2019","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119883_bib125","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-4356","article-title":"Targeting fibroblast activation protein with [177Lu]Lu-FAP-2286 in patients with advanced solid tumors in the phase I LuMIERE trial","author":"McConathy","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib126","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft models","volume":"61","author":"Watabe","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119883_bib127","first-page":"1212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharm. (Basel)"},{"issue":"19","key":"10.1016\/j.biopha.2026.119883_bib128","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib129","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119883_bib130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"7774","key":"10.1016\/j.biopha.2026.119883_bib132","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119883_bib133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119883_bib134","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"issue":"6576","key":"10.1016\/j.biopha.2026.119883_bib135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2026.119883_bib136","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211117","article-title":"Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma","volume":"14","author":"Gunderson","year":"2019","journal-title":"PLoS. One"},{"issue":"7693","key":"10.1016\/j.biopha.2026.119883_bib138","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"7934","key":"10.1016\/j.biopha.2026.119883_bib139","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","article-title":"Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy","volume":"10","author":"Dominguez","year":"2020","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.biopha.2026.119883_bib141","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors","volume":"30","author":"Steeghs","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119883_bib142","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/2767-9764.CRC-24-0185","article-title":"Phase I study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors","volume":"4","author":"Koyama","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib143","first-page":"1639","article-title":"A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib144","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","article-title":"Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer","volume":"6","author":"Narra","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"6005","key":"10.1016\/j.biopha.2026.119883_bib145","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib146","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acs.nanolett.6b04150","article-title":"Protein nanocage mediated fibroblast-activation protein targeted photoimmunotherapy to enhance cytotoxic T cell infiltration and tumor control","volume":"17","author":"Zhen","year":"2017","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.biopha.2026.119883_bib147","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119883_bib148","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib149","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119883_bib150","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119883_bib151","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119883_bib152","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tiv.2016.05.012","article-title":"Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis","volume":"35","author":"Westra","year":"2016","journal-title":"Toxicol. Vitr."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib153","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119883_bib154","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with liver fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119883_bib155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119883_bib156","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Invest."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:00:12Z","timestamp":1790082012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":156,"alternative-id":["S0753332226009194"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119883","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast activation protein-\u03b1 in liver fibrosis and hepatocarcinogenesis: Stromal remodeling, molecular imaging, and theranostic targeting","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119883"}}